LH-21 and Abn-CBD improve β-cell function in isolated human and mouse islets through GPR55-dependent and - independent signalling

<table>
<thead>
<tr>
<th>Journal:</th>
<th><em>Diabetes, Obesity and Metabolism</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>DOM-17-0797-OP.R1</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Original Paper</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>n/a</td>
</tr>
</tbody>
</table>
| Complete List of Authors: | Ruz-Maldonado, Inmaculada; King's College London, Diabetes Research Group  
 Pingitore, Attilio ; King's College London, Diabetes Research Group  
 Liu, Bo; King's College London, Diabetes Research Group  
 Atanes, Patricio; King's College London, Diabetes Research Group; King's College London  
 Huang, Guo Cai; King's College London, Diabetes Research Group  
 Baker, David ; Barts and The London School of Medicine and Dentistry  
 Alonso, Francisco Jose; Universidad de Malaga Facultad de Ciencias, BIOLOGÍA MOLECULAR Y BIOQUÍMICA  
 Bermúdez-Silva, Francisco; Hospital Regional de Malaga - IBIMA, Laboratorio de Investigacion  
 Persaud, Shanta; King's College London, |
| Key Words:        | beta cell function, cannabinoids, glucose metabolism, insulin secretion, islets, type 2 diabetes |
LH-21 and Abn-CBD improve β-cell function in isolated human and mouse islets through GPR55-dependent and -independent signalling

Inmaculada Ruz-Maldonado¹, Attilio Pingitore¹, Bo Liu¹, Patricio Atanes¹, Guo Cai Huang¹, David Baker², Francisco José Alonso³, *Francisco Javier Bermúdez-Silva⁴,⁵, *Shanta J. Persaud¹

¹Department of Diabetes, Faculty of Life Sciences & Medicine, King’s College London, UK.
²Blizard Institute, Barts and The London School of Medicine and Dentistry, UK.
³Canceromics lab, Departamento de Biología Molecular y Bioquímica, Facultad de Ciencias, Instituto de Biomedicina de Málaga (IBIMA), Universidad de Málaga, Spain.
⁴Unidad de Gestión Clínica Intercentros de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain.
⁵Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Málaga, Spain.

*Corresponding authors at:
Department of Diabetes, Faculty of Life Sciences & Medicine, 2.9N Hodkinson Building, King’s College London, Guy’s Campus, London SE1 1UL, UK
Telephone: +44 20 7848 6275
Fax: +44 020 7848 6280
Email: shanta.persaud@kcl.ac.uk

Unidad de Gestión Clínica Intercentros de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Universidad de Málaga, Spain.
Telephone: +34 951 290 226
Fax: +34 951 290 302

Email: javier.bermudez@ibima.eu

Abstract count: 250 words

Word count: 4110 words

References count: 62

Number of figures: 5 (plus one supplementary figure)

Key words: islets, β-cell function, cannabinoids, insulin secretion, proliferation
ABSTRACT

Aims: CB1 and GPR55 are GPCRs expressed by islet β-cells. Pharmacological compounds have been used to investigate their function, but off-target effects of ligands have been reported. This study examined the effects of Abn-CBD (GPR55 agonist) and LH-21 (CB1 antagonist) on human and mouse islet function, and islets from GPR55−/− mice were used to determine signalling via GPR55.

Materials and methods: Islets isolated from human organ donors and mice were incubated in the absence or presence of Abn-CBD or LH-21 and insulin secretion, [Ca²⁺], cAMP, apoptosis, β-cell proliferation and CREB and AKT phosphorylation were examined by standard techniques.

Results: Abn-CBD potentiated glucose-stimulated insulin secretion and elevated [Ca²⁺], in human islets and islets from both GPR55+/+ and GPR55−/− mice. LH-21 also increased insulin secretion and [Ca²⁺], in human islets and GPR55+/+ mouse islets, but concentrations of LH-21 up to 0.1 µM were ineffective in islets from GPR55−/− mice. Neither ligand affected basal insulin secretion or islet cAMP levels. Abn-CBD and LH-21 reduced cytokine-induced apoptosis in human islets and GPR55+/+ mouse islets, and these effects were suppressed following GPR55 deletion. They also increased β-cell proliferation: the effects of Abn-CBD were preserved in islets from GPR55−/− mice, while those of LH-21 were abolished. Abn-CBD and LH-21 increased AKT phosphorylation in mouse and human islets.

Conclusions: This study demonstrated that Abn-CBD and LH-21 improve human and mouse islet β-cell function and viability. Use of islets from GPR55−/− mice suggests that designation of Abn-CBD and LH-21 as GPR55 agonist and CB1 antagonist, should be revised.
1- INTRODUCTION

Cannabinoids are chemicals produced by the cannabis plant (phytocannabinoids) and vertebrates (endocannabinoids) or manufactured commercially (synthetic cannabinoids), and they all act at cannabinoid G protein-coupled receptors (GPCRs) to regulate cell function. CB1 and CB2 are the canonical receptors for cannabinoids, whilst another GPCR, GPR55, which has low sequence homology with CB1 and CB2 [1] and lacks the typical ‘cannabinoid binding pocket’ [2], is also activated by some cannabinoids [3-9]. CB1 and GPR55 have in common an abundant expression in the central nervous system and metabolic tissues and a proposed role in energy balance, [10-16] that may be secondary to their regulation of insulin secretion [10, 11, 13, 14, 17]. We, and others, have demonstrated that CB1 and GPR55 activation in isolated rodent and human islets is associated with insulinotropic properties [10, 11, 13, 14, 18], although a shared consensus in the scientific community has still not been reached with respect to the role of CB1 receptors in islets [19, 20].

Some of the discrepancies between studies may arise through lack of specificity of the cannabinoid ligands used. For example, we have demonstrated that antagonists of CB1 and CB2 have the same stimulatory effects on insulin release from human islets as agonists of these receptors, suggesting that the antagonists act via CB1/CB2-independent pathways [17]. The CB1 antagonist AM251 activates GPR55 [21-23] and we have recently confirmed that GPR55 is expressed by mouse and human islet β-cells, where it plays a positive role in regulating [Ca^{2+}]_i and insulin secretion [14]. In addition, the anti-obesity drug rimonabant, which was developed as a CB1 antagonist, also acts as a GPR55 agonist [21-23] thus suggesting that its anti-obesity and insulin sensitising properties might be mediated, at least in part, by activation of this receptor, rather than by antagonising CB1 [24, 25].

LH-21 (5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole; supplementary Figure 1) was initially identified through screening of 1,2,4-triazole compounds for cannabinoid receptor activity, and it was found to antagonize the effects of the CB1 agonist WIN 55,212-2 [26].
Subsequently, other authors identified LH-21 as a neutral antagonist [24, 27] or weak inverse agonist of CB1 [25] with limited brain penetration, and, similar to rimonabant, it is reported to have anorexigenic effects in animal models of obesity [27, 28]. Treatment of rats with LH-21 for 10 days resulted in a significant up-regulation of GPR55 expression in visceral adipose tissue, suggesting involvement of peripheral GPR55-related regulatory mechanisms in its effects [27]. We have recently demonstrated that LH-21 improves glucose metabolism and reduces anxiety in obese pre-diabetic mice, this latter effect being prevented by a GPR55 antagonist [29]. Due to the promising therapeutic effects of the phytocannabinoid cannabidiol (CBD), synthetic CBD derivatives such as abnormal cannabidiol (Abn-CBD; trans-4-[3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol, supplementary Figure 1) have been synthesized [30]. Abn-CBD has vasodilator effects that were blocked by the CB1 antagonist SR141716A, but were maintained in CB1/CB2 double knockout mice, which led to the proposal that Abn-CBD acted as an agonist at a novel cannabinoid receptor [31]. Abn-CBD is now considered to be a potent and selective GPR55 agonist [11]. It potentiates glucose-dependent insulin secretion from mouse islets and the BRIN-BD11 cell line in vitro [11, 13], and improves glucose tolerance in vivo that is associated with increased insulin sensitivity and β-cell proliferation [11, 13]. The importance of GPR55 in promoting proliferation is supported by studies with the GPR55 agonist O-1602 in various cell types [14, 15, 21, 32-34], which demonstrated activation of pathways known to regulate β-cell mass [35, 36].

In the current study we have investigated the effects of LH-21 and Abn-CBD on the secretory function, apoptosis and proliferation of islets isolated from human non-diabetic donors and C57BL/6 mice. The availability of islets from GPR55−/− mice has allowed us to define whether the effects of these compounds on insulin secretion, [Ca^{2+}], cAMP, β-cell proliferation and apoptosis are mediated via GPR55-dependent or -independent signalling.
2- MATERIALS AND METHODS

2.1 Materials


2.2 Experimental animals

A colony of C57BL/6J GPR55 homozygous knockout mice (GPR55−/−) [14] was maintained at King’s College London, with food and water supplied ad libitum. Age-matched wild-type (GPR55+/+) male C57BL/6 mice were purchased from Envigo (Bicester, UK) and maintained in the same conditions as the GPR55−/− mice prior to islet isolation.

2.3 Isolation of mouse and human islets

Islets were isolated from 8-12 week old male GPR55−/− C57BL/6 mice and age-matched GPR55+/+ mice by collagenase digestion of the exocrine pancreas [37], giving a yield of approximately 200
islets per mouse. All animal procedures were approved by the King’s College London Ethics Committee and carried out in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986. Mouse islets were incubated at 37°C in RPMI-1640 (supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin) for up to 48 h before use. Human islets were isolated from 18 non-diabetic, heart beating pancreas donors (age: 45±2; BMI: 28.5±1.4 kg/m², 6 male, 12 female) at the King’s College Hospital Islet Transplantation Unit with appropriate ethical approval [38]. Human islets were maintained at 37°C in CMRL-1066 (supplemented with 2% human albumin, 4 mM glutamine, 2 mM HEPES, pH 7.2-7.4, and 10 mM nicotinamide) for up to 48 h before use [39].

2.4 Insulin secretion

Assessment of dynamic insulin secretion from groups of 40 mouse or 50 human islets was performed using a temperature-controlled perifusion apparatus [39]. Islets were perifused with a physiological salt solution [40] supplemented with 2 mM glucose or 20 mM glucose in the absence or presence of compounds of interest (vs. vehicle). Perifusate fractions were collected every 2 min and insulin contents were determined by radioimmunoassay [41].

2.5 Single cell calcium microfluorimetry

As islets are clusters of 1-2,000 endocrine cells, for single cell microfluorimetry experiments whole islets were dissociated by short-term incubation with 0.02% EDTA solution, as previously described [42]. Groups of approximately 100,000 dispersed mouse and human islet cells were seeded onto glass coverslips, maintained in culture overnight then loaded with 5 μM Fura-2 AM for 30 min. Cells on coverslips were perifused (37°C, 1 ml/min) with a physiological salt solution [40] containing 2 mM glucose in the absence or presence of test agents. Real-time changes in [Ca²⁺], were determined by illuminating cells alternately at 340 nm and 380 nm, with the emitted light being filtered at 510 nm and data were recorded with a CCD camera every 3 seconds.
2.6 Cyclic AMP

Groups of 4 mouse islets or 5 human islets were transferred to white-walled 96 well plates in HBSS medium supplemented with 10 mM HEPES, 0.2% BSA and 2 mM IBMX, and incubated for 1 h at room temperature in the absence or presence of test agents. Islet cAMP levels were quantified according to the manufacturer’s protocol, with measurement of the fluorescence emission intensity ratio at 665/620 nm using a Pherastar FS microplate reader (BMG LABTECH Ltd., Bucks, UK).

2.7 Caspase 3/7 activities

Mouse and human islets were maintained in culture for 24 h in the absence or presence of 0.1 μM LH-21 or 10 μM Abn-CBD. Groups of 3 mouse or 5 human islets were then incubated for a further 20 h in RPMI-1640 or CMRL with 2% FBS (mouse) or 0.2% albumin (human) supplemented with a cytokine cocktail (0.025 U/μl IL-1β, 1 U/μl TNFα and 1 U/μl IFNγ), and islet cell apoptosis was determined using the Caspase 3/7 Glo® assay [39].

2.8 Islet β-cell proliferation

Islets isolated from GPR55+/+ and GPR55−/− mice were incubated for 5 days at 37°C (95% air/5% CO₂) in RPMI-1640 supplemented with 0.1 μM LH-21, 1 μM Abn-CBD or vehicle (0.007% DMSO) and 1 mg/ml BrdU. Media and supplements were refreshed every 48 h. Islets were then pelleted at 135 g, fixed with 4% paraformaldehyde and embedded in paraffin. 5 μm thick sections were dewaxed then antigens were retrieved using citrate buffer (10 mM citric acid, 0.05% Tween 20, pH 6.0). Sections were incubated overnight at 4°C with primary anti-insulin (guinea pig) and anti-BrdU (mouse) antibodies at 1:200 and 1:100 dilutions, respectively, then incubated with anti-guinea pig AlexaFluor® 594 and anti-mouse AlexaFluor® 488 antibodies (1:50 dilution) for 1 h at room
temperature. Images were visualised using a Nikon Eclipse TE2000-U microscope and analysed in a non-blinded manner using Image J software (https://imagej.net/) [43].

2.9 Western blotting

Groups of 200 mouse or human islets were incubated for 30 min in a buffer containing 25 mM glucose in the absence or presence of Abn-CBD or LH-21. Islets were then lysed in the presence of phosphatase and protease inhibitors and protein contents were quantified by the BCA method. Forty micrograms of lysates were fractionated on 4-12% polyacrylamide gels (1 h, 200 V), transferred onto 0.2 μm PVDF membranes, blocked with 5% BSA in Tris-buffered saline, 0.1% Tween-20 (TBST) for 1 h at room temperature and then probed overnight at 4°C with rabbit anti-phospho CREB, anti-total CREB, anti-phospho-AKT and anti-total-AKT antibodies, all diluted 1:1000 in 5% BSA in TBST. The membranes were then incubated with anti-rabbit HRP-conjugated secondary antibody (1:10000) for 1 h at room temperature and exposed to X-ray film after addition of ECL substrate [44].

2.10 Statistical Analyses

Differences between selected pairs of data were analysed by unpaired Student’s t-test while differences between several groups were analysed by one-way ANOVA followed by Tukey’s, Dunnett’s Multiple Comparison or Newman-Keuls Multiple Comparison post tests.

3- RESULTS

3.1 Effects of Abn-CBD and LH-21 on glucose-induced insulin secretion

As shown in Figure 1A, exposure of human islets to increasing concentrations of Abn-CBD (0.1-10 μM) resulted in concentration-dependent potentiation of glucose-induced insulin secretion. The stimulatory effects were rapid in onset, and readily reversible upon removal of Abn-CBD. LH-21 (0.1-1 μM) also reversibly potentiated insulin secretion from human islets (Figure 1B), with a similar
stimulatory profile to that observed for Abn-CBD. Exposure of human islets to Abn-CBD or LH-21 was 
without effect on basal insulin secretion at 2 mM glucose (Figures 1C, 1D).

Abn-CBD (Figures 1E, 1F) and LH-21 (Figures 1H-1J) enhanced glucose-induced insulin secretion from 
GPR55\(^{+/-}\) mouse islets, as they did from human islets. Stimulatory effects of 1 \(\mu M\) (Figure 1E) and 10 
\(\mu M\) Abn-CBD (Figure 1F) were also observed in islets isolated from GPR55\(^{-/-}\) mice, and the 
potentiating effect of 10 \(\mu M\) Abn-CBD was actually accentuated following GPR55 deletion. In 
contrast, potentiation of insulin secretion by low concentrations of LH-21 was completely dependent 
on GPR55, with islets from GPR55\(^{-/-}\) mice showing no response at all to 1nM and 0.1 \(\mu M\) of this 
compound (Figure 1H, 1I). Interestingly, however, it was found that deletion of GPR55 did not 
abrogate the stimulation of insulin secretion by 1 \(\mu M\) LH-21, and GPR55\(^{-/-}\) islets secreted more 
insulin than their wildtype counterparts in response to this higher concentration (Figure 1J). Abn-
CBD and LH-21 did not significantly stimulate basal insulin secretion from GPR55\(^{+/-}\) or GPR55\(^{-/-}\) 
mouse islets (Figure 1G, 1K).

### 3.2 Effects of LH-21 and Abn-CBD on islet \([Ca^{2+}]\), and cAMP levels

The requirement for GPR55 to mediate the stimulatory effects of 1 nM and 0.1 \(\mu M\) LH-21 on insulin 
secretion was unexpected, given that LH-21 is considered to be an antagonist or inverse agonist at 
CB1. We therefore explored the effects of LH-21 and Abn-CBD on changes in \([Ca^{2+}]\), since it is known 
that GPR55 couples to \(G_\alpha_5\) and \(G_{\alpha_13}\) pathways [14-16] that regulate \(Ca^{2+}\) levels.

Dispersed islet cells from both GPR55\(^{+/-}\) (Figures 2A, 2C) and GPR55\(^{-/-}\) mice (Figures 2B, 2D) 
responded to an increase in glucose concentration from 2 mM to 20 mM with a rapid and sustained 
elevation in \([Ca^{2+}]\). Exposure of GPR55\(^{+/-}\) islet cells to 0.1 \(\mu M\) LH-21 led to a small increase in \([Ca^{2+}]\), 
(Figure 2A) and this response was lost following deletion of GPR55 (Figure 2B), in agreement with 
the insulin secretion data (Figure 1I), demonstrating that low concentrations of LH-21 act via GPR55. 
Also consistent with the secretion data, 1 \(\mu M\) Abn-CBD promoted increases in \([Ca^{2+}]\), in dispersed 
islets from both GPR55\(^{+/-}\) and GPR55\(^{-/-}\) mice (Figures 2C, 2D), indicating that Abn-CBD is able to
stimulate elevations in \([\text{Ca}^{2+}]_i\) and insulin secretion independently of GPR55. In all tested batches of islets the ATP-sensitive channel blocker, tolbutamide, stimulated reversible increases in \([\text{Ca}^{2+}]_i\), demonstrating that the ability to control the membrane potential was preserved after exposure to LH-21 and Abn-CBD. Dispersed human islets also responded to both Abn-CBD and LH-21 with increases in \([\text{Ca}^{2+}]_i\). In particular, 0.1 μM Abn-CBD reversibly increased \([\text{Ca}^{2+}]_i\), while 10 μM Abn-CBD induced a sustained elevation in \([\text{Ca}^{2+}]_i\) (Figure 2E); 0.1 μM LH-21 induced a rapid, reversible increase, in \([\text{Ca}^{2+}]_i\), and the response to 1 μM LH-21 was sustained after the drug had been removed from the perifusing buffer (Figure 2F).

CB1 receptors are coupled to G to reduce cAMP generation [45], so we determined whether Abn-CBD or LH-21 had any effects on islet cAMP levels. These experiments indicated that neither ligand affected basal cAMP in islets isolated from GPR55\(^{+/+}\) (Figure 2G) or GPR55\(^{-/-}\) (Figure 2H) mice, whereas the GLP-1 agonist exendin-4 produced the expected elevation in cAMP. In addition, Abn-CBD and LH-21 did not inhibit forskolin-stimulated cAMP accumulation, but this was significantly decreased by the \(\alpha_2\) adrenergic agonist clonidine, as expected (Figure 2I, 2J). Similar observations were made in human islets, where Abn-CBD and LH-21 neither stimulated (Figure 2K) nor inhibited (Figure 2L) cAMP generation.

3.3 Abn-CBD and LH-21 protect islets against cytokine-induced apoptosis via GPR55

GPR55 has been implicated in protecting islets from programmed cell death [15, 46], thus in the current study caspase 3/7 activities were measured in islets from GPR55\(^{+/+}\) and GPR55\(^{-/-}\) mice. These experiments indicated that Abn-CBD and LH-21 did not affect basal levels of apoptosis in islets from GPR55\(^{-/-}\) mice but they significantly reduced apoptosis induced by a cytokine cocktail (Figure 3A). However, although the cannabinoid ligands exerted protective effects, they did not fully block cytokine-induced apoptosis, which was significantly elevated above basal even in the presence of Abn-CBD or LH-21. Cytokines also elevated caspase 3/7 activities in islets from GPR55\(^{-/-}\) mice and while there were small reductions in the presence of Abn-CBD or LH-21 these were not statistically
significant (Figure 3B). Interestingly, as shown in Figure 3C, Abn-CBD and LH-21 totally reverted cytokine-induced apoptosis in human islets.

3.4 LH-21 and Abn-CBD stimulate β-cell proliferation

Double immunofluorescence staining of islets from GPR55+/+ and GPR55−/− mice for insulin and BrdU expression indicated that 5 days’ exposure to 1 μM Abn-CBD or 0.1 μM LH-21 increased BrdU incorporation into proliferating β-cells of wildtype mice (Figures 4A, 4B). These stimulatory effects of LH-21 were abolished following GPR55 deletion, and while Abn-CBD-induced β-cell proliferation was reduced in GPR55−/− islets it was still able to significantly stimulate BrdU incorporation into β-cells (Figures 4A, 4B). Further quantification of immunofluorescence images indicated that the stimulatory effects of Abn-CBD and LH-21 on BrdU incorporation in GPR55+/+ islets were associated with significantly increased numbers of β-cells per islet (Figure 4C) and increased islet area (Figure 4D), and the effects of LH-21 were dependent on GPR55 since it failed to trigger the same responses in the GPR55−/− islets. These effects of LH-21 and Abn-CBD to promote β-cell proliferation and increase islet size were independent of any effect on individual β-cell area (Figure 4E).

3.5 Effects of Abn-CBD and LH-21 on CREB and AKT phosphorylation in mouse and human islets

Exposure of mouse islets for 30 min to 10 μM Abn-CBD or 0.1 μM LH-21 in the presence of 25 mM glucose increased levels of phosphorylated CREB (P-CREB) (Figure 5A), and these ligands also promoted increases in Akt phosphorylation (P-Akt) in mouse islets (Figure 5B). Abn-CBD and LH-21 also increased P-AKT in human islets (Figure 5D), but in experiments with four different batches of human islets they had no effect on P-CREB (Figure 5C).

4- DISCUSSION

Despite confirmation of the expression of CB1 and GPR55 by both rodent and human β-cells [10, 14, 18, 19, 47, 48], the role played by the endocannabinoid system in the modulation of islet secretory...
activity is still far from being completely understood. For example, while the majority of studies suggest that activation of CB1 receptors increases insulin secretion [47, 49-51], others point to the opposite effects [19, 20]. The reasons for the controversies are likely to lie in the experimental models used, the selectivity of the ligands and the difficulties in addressing the intracellular coupling where cannabinoid receptors signal via more than one heterotrimeric G-protein [15, 48]. Indeed, various factors such as differences in the concentrations of the agonists and antagonists used, diversities in the experimental design and impact of circulatory factors such as incretins in the in vivo studies [19], can all contribute to the variabilities between studies. In the current study we measured insulin release from isolated mouse and human islets under dynamic conditions, where the continuous flow of perifusing buffers minimises autocrine and paracrine effects of secreted products that may occur in static incubation protocols [52]. In terms of ligand selectivity, it has been demonstrated that some CB1 antagonists such as AM251 and rimonabant can also act as agonists for GPR55 [23], which is expressed by islet β-cells and whose activation increases insulin secretion from both human and mouse islets [10, 11, 13, 14], and this may have led to differences in interpretation of earlier studies.

Since LH-21, an inverse agonist/neutral antagonist of CB1, shows structural similarities with AM251 and rimonabant [24, 25, 27-29], we investigated whether its activation of islet GPR55 could underlie at least some of its reported positive effects on glucose management [24, 27-29]. An earlier study used a static incubation protocol to show that the CB1 antagonists AM251 and JD-5037 increased insulin release from human islets [19], and in the current study we employed perifusion experiments to demonstrate that LH-21 also promoted insulin secretion from human islets. However, we found that the potentiation of insulin release by lower concentrations of LH-21 (1 nM and 0.1 µM) was lost in islets isolated from GPR55−/− mice demonstrating that the insulinotropic effects were not secondary to antagonism of islet CB1 receptors, but were a consequence of LH-21 binding to islet GPR55. Thus, these data indicate that caution should be exerted when concluding that the effects
evoked by LH-21 are mediated exclusively by CB1, especially when it is used at nanomolar concentrations. Nevertheless, we found that 1 μM LH-21 was able to stimulate insulin secretion following GPR55 deletion, indicating signalling in a GPR55-independent manner at higher concentrations of LH-21. This stimulatory effect most likely occurs via an undefined receptor, as we previously observed for 10 μM AM251 in human islets [17].

As a parallel investigative strategy we studied the requirement of GPR55 for insulin secretion induced by Abn-CBD, a cannabinoid that is reported to be at least 10-fold more selective for GPR55 than for CB1 or CB2 [16]. It has previously been demonstrated that Abn-CBD increases insulin secretion from BRIN-BD11 insulin-secreting cells and mouse islets [11]. In the current study we confirmed that Abn-CBD potentiated glucose-induced insulin secretion from mouse islets and we also demonstrated, for the first time, that it has similar stimulatory effects in human islets. However, despite its reported selectivity as a GPR55 agonist, Abn-CBD stimulated elevations in insulin release in islets from GPR55-/- mice, indicating that at concentrations of 1 μM and above it exerts GPR55-independent effects in islets.

The insulin secretion potentiating properties of Abn-CBD and LH-21 were accompanied by increases in [Ca^{2+}] in both human and mouse islets. The elevation in [Ca^{2+}] evoked by 0.1 μM LH-21 required the expression of GPR55, in agreement with the insulin secretory response to that low concentration of the drug and confirming that LH-21 acts as a GPR55 agonist in islets. However, Abn-CBD induced increased [Ca^{2+}] in islets from GPR55-/- mice, consistent with the insulin secretion data and suggesting that it acts through another receptor. A possible candidate is GPR18, which is activated by Abn-CBD [53], expressed by islets [54], and it has been reported that GPR18 activation is associated with transient elevation of [Ca^{2+}] [55]. Nothing is known about the functional role of GPR18 in islets, but it has been reported that the GPR18 agonist N-arachidonylglycine promotes elevations in β-cell [Ca^{2+}], and potentiates insulin secretion from rat islets [56].
There is a growing body of evidence suggesting that the endocannabinoid system has a role in the regulation of cell proliferation and apoptosis [57-59]. We have previously reported that CB1 and CB2 agonists protect mouse islets from apoptosis [60], and we recently demonstrated that LH-21 delivery to pre-diabetic mice has anti-inflammatory and cytoprotective effects [29]. In the current study we showed that LH-21 has direct anti-apoptotic effects in isolated human and mouse islets and the use of islets from GPR55−/− mice indicated that, as for stimulation of insulin secretion and [Ca^{2+}]_i, this was GPR55-mediated. Abn-CBD also possessed anti-apoptotic effects in islets but, in contrast to its GPR55-independent effects on insulin secretion, it failed to significantly protect against cytokine-induced apoptosis in GPR55−/− islets. In addition, incubation of isolated islets for 5 days in the presence of 1 μM Abn-CBD or 0.1 μM LH-21 stimulated islet β-cell proliferation. The beneficial effects of LH-21 were strictly dependent on GPR55. Abn-CBD-stimulated BrdU incorporation was reduced, but not abolished, in GPR55−/− islets, indicating that GPR55 is required for some of its pro-proliferative effects but that it acts via another receptor to fully stimulate β-cell mass expansion. Analysis of the untreated islets also indicated that endogenous GPR55 is required for normal maintenance of β-cell mass, since vehicle-treated islets from GPR55−/− mice had fewer proliferating β-cells, which was associated with decreased numbers of β-cells per islet and reduced islet area.

In terms of identifying signalling cascades by which LH-21 and Abn-CBD can regulate β-cell proliferation and apoptosis, it has been reported that the cannabinoid system can activate the serine/threonine kinase AKT and the transcription factor CREB [61, 62]. Our observations that LH-21 and Abn-CBD stimulated AKT phosphorylation in mouse and human islets support a role for GPR55 signalling via this kinase in islets. However, increased CREB phosphorylation was only observed in mouse islets, suggesting either species-specific signalling downstream of GPR55 or it might reflect the capacity of the ligands to activate multiple receptors, which may be differentially expressed in mouse and human islets.
In conclusion, the cannabinoid ligands LH-21 and Abn-CBD increase insulin secretion from human and mouse islets, most likely via Ca\textsuperscript{2+}-regulated intracellular pathways, protect β-cells from apoptosis and they foster increased β-cell proliferation. The use of islets isolated from GPR55\(^{-/-}\) mice allowed the elucidation of the contribution of GPR55-mediated signalling in the functional effects of LH-21 and Abn-CBD and our work provides the first evidence of LH-21 acting as a GPR55 agonist in islets. Furthermore, our data clearly demonstrate that Abn-CBD cannot be considered to be a selective GPR55 agonist, at least in islets. The ability of LH-21 to potentiate glucose-induced insulin secretion at nanomolar concentrations, its capacity to protect islets from apoptosis and stimulate β-cell proliferation, and its protected profile at the CNS level in terms of inducing anxiety/depressive traits [28] suggest that a re-evaluation of this molecule as an active tool for the regulation of glucose management in diabetic patients is warranted.

Acknowledgements

We are grateful to the relatives of organ donors for human pancreases for islet isolation. This project was supported by grants from Diabetes UK [11/0004307]; Instituto de Salud Carlos III (ISCIII), Ministerio de Sanidad, Gobierno de España, Spain, (13/00309 to F.J.B.S. and FI11/00636 to I.R.M., co-funded by FEDER, EU, “Una manera de hacer Europa”), the European Foundation for the Study of Diabetes (EFSD) (Albert Renold Fellowship to I.R.M.) and the Consejería de Salud, Junta de Andalucía, Spain (C-0070-2012 to F.J.B.S). CIBERDEM is an initiative of the Instituto de Salud Carlos III.

Author contributions

S.J.P., F.J.B.S. and I.R.M. conceived, designed and supervised the study. I.R.M., A.P., L.B., and P.A., performed the experiments. D.B. provided the GPR55 null mice and G. C. H. provided the isolated

wrote the paper. All the authors revised the manuscript.

References


[18] Li C, Bowe JE, Jones PM, Persaud SJ. Expression and function of cannabinoid receptors in mouse islets. Islets. 2010; 2: 293-302


[41] Jones PM, Salmon DM, Howell SL. Protein phosphorylation in electrically permeabilized islets of Langerhans. Effects of Ca2+, cyclic AMP, a phorbol ester and noradrenaline. The Biochemical journal. 1988; 254: 397-403


[48] Li C, Jones PM, Persaud SJ. Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas. Pharmacology & therapeutics. 2011; 129: 307-320


[52] Li C, Jones PM, Persaud SJ. Cannabinoid receptors are coupled to stimulation of insulin secretion from mouse MIN6 beta-cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2010; 26: 187-196


Figure Legends

FIGURE 1: Effects of Abn-CBD and LH-21 on dynamic insulin secretion from human and mouse islets.

Dynamic profiles of insulin secretion from islets isolated from human donors (A-D) and from GPR55+/+ and GPR55−/−mice (E-K) in response to Abn-CBD and LH-21. The horizontal arrows indicate the duration of exposure to 2 mM and 20 mM glucose and the period of perifusion with Abn-CBD and LH-21. Data are expressed as mean ± SEM of experiments with islets from 6 separate human donors or 5 independent experiments with mouse islets. **p<0.01 and ***p<0.001: response of islets to 20 mM glucose vs. 2 mM glucose; ***p<0.001 and ****p<0.0001 vs. secretion in the presence of vehicle (experiments with human islets) **p<0.01 and ***p<0.001 response of islets to 20 mM glucose vs. 2 mM glucose; **p<0.01 and ***p<0.001 secretion from GPR55+/+ vs. GPR55−/− islets (experiments with mice islets). Data were analysed by unpaired Student’s t tests.
FIGURE 2: Effects of Abn-CBD and LH-21 on [Ca^{2+}]_i and cAMP in mouse and human dispersed islets.

Dynamic profiles of [Ca^{2+}]_i in Fura-2-loaded dispersed GPR55^{+/+} (A, C), GPR55^{-/-} (B, D) and human (E, F) islets. The horizontal arrows indicate the duration of exposure to 2 mM and 20 mM glucose and the period of perifusion with Abn-CBD, LH-21 and the sulphonylurea tolbutamide. Data of the 340/380 fluorescence ratios are expressed as mean + SEM; 30 β-cells from 5 independent experiments with mouse islets and 8 β-cells from 3 independent experiments with human islets. Intracellular cAMP levels in GPR55^{+/+} (G, I), GPR55^{-/-} (H, J) and human (K, L) islets. Data are expressed as mean + SEM of 6 replicates within individual experiments using one batch of human islets and islets from 2 GPR55^{+/+} and 2 GPR55^{-/-} mice. **** p<0.0001 exendin-4 vs. basal; # p<0.1 and ## p<0.01 clonidine vs. forskolin. Data were analysed by One-way ANOVA, Dunnett’s multiple comparisons post test.

FIGURE 3: Effects of Abn-CBD and LH-21 on mouse and human islet apoptosis.

Effects of Abn-CBD and LH-21 on apoptosis of GPR55^{+/+} (A) and GPR55^{-/-} (B) islets and human (C) islets that had been maintained for 20 h in the absence or presence of a cytokine cocktail. Apoptosis was detected by luminescence assay of caspase 3/7 activities. Data are expressed as mean + SEM of 3 independent experiments for both mouse and human islets, each of 8-10 replicates. ** p<0.01, ### p<0.001, ns p>0.05. Data were analysed by one-way ANOVA with repeated measures followed by Tukey’s multiple comparison post tests.

FIGURE 4: Effects of Abn-CBD and LH-21 on β-cell proliferation in GPR55^{+/+} and GPR55^{-/-} mouse islets. Immunofluorescence of paraffin-embedded sections of islets from GPR55^{+/+} or GPR55^{-/-} mice after 5 days of exposure to 1mg/ml BrdU in vitro in the presence or absence of Abn-CBD or LH-21, and probed with antibodies directed against insulin (red) and BrdU (green). A) Images of representative immunostained islets; scale bar = 50 μm. Post-acquisition analyses were performed
with Image J® and are shown in panels B-E: B) number of BrdU and insulin positive cells per islet; C) number of β-cells (insulin positive cells) per islet; D) mean islet area (μm²); E) individual β-cell area, calculated by dividing the mean islet area (μm²) by the number of β-cells per islet. *p<0.05, **p<0.01 and ***p<0.001. In panel B and C, #p<0.05 and ###p<0.001 for Abn-CBD treated GPR55−/− islets vs. their vehicle counterparts. Data were obtained from multiple acquisitions of 45-75 islets per condition, each with a minimum of 6 paraffin sections for analysis. Data were analysed by one way ANOVA followed by Dunnett’s (B) and Newman-Keuls (C-E) multiple comparison post tests.

FIGURE 5. Effects of Abn-CBD and LH-21 on CREB and AKT phosphorylation in mouse and human islets.

Blotting of mouse (A, B) and human (C, D) islet lysates with antibodies directed against phospho-CREB (P-CREB), CREB, phospho-AKT (P-AKT) and AKT, with the relative densitometric analyses of the immunoreactive proteins normalised as ratios between the phosphorylated and non-phosphorylated forms. Data in the graphs are shown as mean ± SEM of 4 independent experiments with mouse and human islets, each with 200 islets per condition. *p<0.05, **p<0.01 and ***p<0.001. Results were analysed by one-way ANOVA with repeated measures followed by Dunnett’s Multiple Comparison post test.

SUPPLEMENTARY FIGURE 1. Structures of LH-21 (A) and Abn-CBD (B).
Figure 1 (A-D)

A) 20 mM glucose

Abn-CBD

- 10 μM
- 1 μM
- 0.1 μM
- Vehicle

2 mM glucose

B) 20 mM glucose

LH-21

- 1 μM
- 0.1 μM
- Vehicle

2 mM glucose

C) 2 mM glucose

10 μM Abn-CBD

D) 2 mM glucose

0.1 μM LH-21
Figure 1 (E-G)

E) 20 mM glucose

GPR55+/+

GPR55-/-

1 µM Abn-CBD

F) 20 mM glucose

GPR55+/+

GPR55-/-

10 µM Abn-CBD

G) 20 mM glucose

GPR55+/+

GPR55-/-

10 µM Abn-CBD

Time (min)
Insulin (pg islet⁻¹ min⁻¹)
Figure 1 (H-K)

H) 20 mM glucose

GPR55+/+
GPR55-/-

1 nM LH-21

2 mM glucose

I) 20 mM glucose

GPR55+/+
GPR55-/-

0.1 μM LH-21

J) 20 mM glucose

GPR55+/+
GPR55-/-

1 μM LH-21

K) 20 mM glucose

GPR55+/+
GPR55-/-

2 mM glucose

0.1 μM LH-21
A) 2 mM glucose 20 mM glucose

B) 2 mM glucose 20 mM glucose

C) 2 mM glucose 20 mM glucose

D) 2 mM glucose 20 mM glucose

E) 2 mM glucose 20 mM glucose

F) 2 mM glucose 20 mM glucose

Time (min)

340/380 ratio

0.50 0.60 0.70

2 mM glucose 20 mM glucose

0.1 μM LH-21 Tolbutamide

1 μM Abn-CBD Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM Abn-CBD 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide

0.1 μM LH-21 100 μM Tolbutamide
Figure 2 (G-L)

**G)**

GPR55+/+(G_s)

- Basal
- 10 μM Abn-CBD
- 0.1 μM LH-21
- 20 nM Exendin-4

**H)**

GPR55−/− (G_s)

- Basal
- 10 μM Abn-CBD
- 0.1 μM LH-21
- 20 nM Exendin-4

**I)**

GPR55+/+(G_i)

- 1 μM Forskolin
- 10 μM Abn-CBD
- 0.1 μM LH-21
- 1 μM Clonidine

**J)**

GPR55−/− (G_i)

- 1 μM Forskolin
- 10 μM Abn-CBD
- 0.1 μM LH-21
- 1 μM Clonidine

**K)**

Human islets (G_s)

- Basal
- 10 μM Abn-CBD
- 0.1 μM LH-21
- 20 nM Exendin-4

**L)**

Human islets (G_i)

- 1 μM Forskolin
- 10 μM Abn-CBD
- 0.1 μM LH-21
- 1 μM Clonidine
Figure 3

A) Caspase 3/7 activities (luminiscence units/islet)

B) Caspase 3/7 activities (luminiscence units/islet)

C) Caspase 3/7 activities (luminiscence units/islet)
Figure 4 (A)

A) Vehicle  1 μM Abn-CBD  0.1 μM LH-21

GPR55+/−  GPR55−/−

156x124mm (300 x 300 DPI)
Figure 4 (B-E)

B) 

**BrdU + insulin cells per islet**

- GPR55^{+/+}
- GPR55^{+-/-}

<table>
<thead>
<tr>
<th>Treatment</th>
<th>GPR55^{+/+}</th>
<th>GPR55^{+-/-}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 μM Abn-CBD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1 μM LH-21</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C) 

**β-cells per islet**

- GPR55^{+/+}
- GPR55^{+-/-}

D) 

**Islet area (μm²)**

(respect to β-cells)

- GPR55^{+/+}
- GPR55^{+-/-}

E) 

**Individual β-cell area (μm²)**

- GPR55^{+/+}
- GPR55^{+-/-}
Figure 5

A) 10 μM 0.1 μM
Vehicle Abn-CBD LH-21

P-CREB/CREB

P-CREB

CREB

B) 10 μM 0.1 μM
Vehicle Abn-CBD LH-21

P-Akt/Akt

P-Akt

Akt

25 mM glucose (30 min)

Band intensity (% relative to vehicle)

200

150

100

50

0

Vehicle 10 μM 0.1 μM 0.1 μM

LH-21

P-CREB/CREB

P-Akt/Akt

25 mM glucose (30 min)

Band intensity (% relative to vehicle)

200

150

100

50

0

Vehicle 10 μM 0.1 μM 0.1 μM

LH-21

25 mM glucose (30 min)

Band intensity (% relative to vehicle)

200

150

100

50

0

Vehicle 10 μM 0.1 μM 0.1 μM

LH-21
Supplementary Figure 1
Responses to Referees' comments

Referee: 1
No responses required.

Referee: 2
We are pleased that the reviewer considered this to be “a comprehensive and carefully conducted pharmacological study on molecules targeting a medically relevant group of G protein coupled receptors”.

In response to the specific comments:

1. The authors shall better introduce the two molecules. How were they identified and what kind of structure do they have?
   We have now modified the Introduction to provide the requested information on LH-21 and Abn-CBD (pages 4 and 5), and included a supplementary Figure of Abn-CBD and LH-21 structures.

2. The authors shall explain why they used dispersed islets in calcium measurements.
   We have now provided this information in the Methods section (page 7).

3. Figure 1: What are the effects of LH-21 and Abn-CBD on insulin release at low glucose concentrations?
   We have now carried out additional experiments to determine the effects of Abn-CBD and LH-21 on insulin secretion from perifused islets at a sub-stimulatory glucose concentration and have included these new data as panels C, D, G and K in Figure 1 of the revised manuscript, and commented on the results obtained (pages 9-10).

4. Figure 1: The authors shall use a more consistent way to present error bars.
   We have now presented the error bars as +SEM for all 11 panels of perifusion data in Figure 1.

5. Figure 3: Is it possible to show this Figure as dotplots? Or, alternatively, show SDs rather than SEMs?
   It is usual for measurements of islet caspase activities to be presented as bar charts rather than dot plots, and we think that the data in the three panels of Figure 3 clearly demonstrate the GPR55-dependent anti-apoptotic effects of LH-21 and Abn-CBD. However, we are happy to re-plot the data as dotplots if the Editor thinks that this is necessary.

6. Figure 3C: Were the effects on human islets also observed in islets from a different human donor? Please indicate whether the results were replicated or not.
   Overall we used islets from 18 human donors for this study. The data shown in Figure 3C were obtained using islets from 3 separate donors. We have now modified the Figure legend to clarify this.

7. Figure 4A: Please use a scale bar instead of 20x.
   We have now provided scale bars to the panels in Figure 4A, as requested.

8. Figure 4B-D: Was the image analysis done in a blinded or not blinded manner? Please indicate.
   The image analysis was performed in a non-blinded manner by an experienced researcher. We have now modified the Methods section to clarify this (page 8).
Referee: 3
We are pleased that the referee considered that “The performed experiments are coherent with their purpose” and the article “is potentially of interest”. However, we recognise that the referee raised several concerns and we have responded to the comments below.

The methods are not well described/some experimental procedures need to be clarified.
We have modified the Methods section to provide some additional detail on the experimental procedures (pages 6-9), but we are limited by including everything in the word count that is available. We have provided reference to our previously published papers with additional detail on the methods used (refs 37, 38, 39, 41, 42, 43 and 44).

It is unclear when the experiment was done on islets to know if more than one mouse has been used/the number of individual donor for experiments using human islets.
Experiments were performed on islets from multiple mice and human donors. We have indicated in the Methods section that approximately 200 islets were obtained per mouse pancreas, and that we obtained islets from 18 human donors (page 7). Information has been provided in the Figure legends to clarify the numbers replicates of experiments performed.

The authors have reported that the GPR55 selective drug Abn-CBD potentiates insulin secretion in mouse islets (fig 1C and D), but there is no explanation for the results obtained from GPR55-/- islets. It is unclear why the drug is acting. This result does not strengthen their demonstration about LH-21.
We agree that our observation of enhanced glucose-induced insulin secretion in response to 10µM Abn-CBD in islets from GPR55-/- mice (Figure 1D) was unexpected and our data have demonstrated that it is not a GPR55-selective drug. We have considered in the Discussion whether the GPR55-independent effects of Abn-CBD are mediated by GPR18, which is also expressed by islets (page 14).

The results given in figure 2 are obtained using Fura2 fluorescence recording, but it is surprising to get such small variation in signal. Base lines are not always stable and some other, more appropriate, (exendin IV rather than tolbutamide) positive control should have been done.
The data presented in the panels in Figure 2 show mean-SEM data for Fura-2 fluorescence ratios. The small variation in signal is most apparent when we were recording from numerous islet cells (n=30 cells for panels A and B), with larger variability, as expected when fewer cells were used (n=8 cells for panels E and F). We do not think that exendin-4 is a superior positive control to tolbutamide as the sulphonylurea directly depolarises β-cells through closure of KATP channels to elevate [Ca^{2+}], while exendin 4 is Gs-coupled to promote cAMP elevation.

In experiments performed in order to analyze b-cell proliferation, the authors have showed that Abn-CBD effect is not fully abolish on GPR55/- mice. Again this point is puzzling. It is not obvious why the authors have chosen to focus on LH-21 instead of the reported GPR55 selective agonist Abn-CBD.
We are not sure of the precise point being made by the referee here, as we think that we focused equally on Abn-CBD and LH-21. The ability of Abn-CBD to significantly promote BrdU incorporation into β-cells of GPR55-/- mice is unexpected for an agonist that is considered to be selective for GPR55, but these are the data that we obtained and they clearly indicate that Abn-CBD has GPR55-independent effects. We have expanded the Discussion section to comment on this (page 15).

In signaling experiments performed on mice and human islets, the authors have focused on P-
CREB and P-Akt. Fig 5B and 5C are puzzling. In fig 5B the vehicle control is not negative, this results may explain the lack of clear activation in mouse. Also in fig 5C it is surprising that P-CREB is not stimulated, a positive control should have been done.

We agree with the referee that the Akt phosphorylation induced by 25mM glucose alone (vehicle control) in Figure 5B made it difficult to determine whether Abn-CBD or LH-21 had stimulatory effects. We have carried out four separate experiments using mouse islets and analysis of all of these experiments has indicated a significant elevation in Akt phosphorylation by Abn-CBD and LH-21. We have now included a more representative western blot in Figure 5B. However, the lack of stimulation of CREB phosphorylation by Abn-CBD and LH-21 was evident in experiments using human islets from four different donors. We think that the experimental protocol was appropriate since CREB phosphorylation was evident using the phospho-CREB antibody, but enhanced phosphorylation was not observed with human islets (Figure 5C) as it was for mouse islets (Figure 5A).

Using a GPR55's selective drug as control, instead of Abn-CBD, should have been a better choice.

One of the aims of the current study was to determine whether Abn-CBD could be considered to be a selective GPR55 agonist in islets and this would not have been possible if we had used a GPR55-selective drug. In fact, we have recently reported that O-1602 is a selective agonist for GPR55 (Liu et al. Diabetes, Obesity & Metabolism 2016; 18: 1263-1273; reference 14 in the current manuscript), and it would not have been appropriate to replicate the experiments that we have already published.

Referee: 4

We are pleased that the referee thought that “The present study showed a specific focus” and raised only minor comments.

In response to the specific comments:

Calcium-related downstream pathways, such as CAMKII could be studied in LH-21 and Abn-CBD treated GPR55 +/+ or -/- islets.

We agree that it would be interesting to define the pathways downstream of elevations in intracellular calcium but this is outside of the scope of the current study, which already contains five multi-panelled figures (and now with additional data as indicated in the responses to all referees).

What is the intracellular cAMP response to LH-1 and Abn-CBD in GPR55 +/+ and -/- islets?

We have now carried out additional experiments to determine the effects of LH-21 and Abn-CBD on generation of cAMP in islets from WT and GPR55 mice and in islets from human donors. These data have been included as panels G-L of Figure 2, and have been commented on in the text on (page 11).

It would be better to add “ex vitro” or “isolated islets” in the title. Otherwise, readers may expect the whole body glucose metabolism effect of LH-21 and Abn-CBD, and their relations with GPR55 in the present study. In addition, by stating the ex vivo, it will be more clear that the effect is directly on pancreatic islets, but not secondary effect from the improvement of glucose homeostasis.

We agree that it is important to indicate in the title that this work relates to experiments carried out ex vivo so we have now modified the title to reflect that the work was performed using isolated islets.